https://www.selleckchem.com/pr....oducts/rogaratinib.h
Identifying mutation-carrying relatives of patients with hereditary cancer syndromes via cascade testing is an underused first step in primary cancer prevention. A feasibility study of facilitated genetic testing of at-risk relatives of patients with a known pathogenic mutation demonstrated encouraging uptake of cascade testing. Our primary objective is to compare the proportion of genetic testing of identified first-degree relatives of probands with a confirmed mutation randomized to a facilitated cascade testing strategy versus st
Like
Comment
Share
